Summary.-Peripheral blood mononuclear cells will lyse antibody-treated human erythrocytes. Using Group A red cells and a hyperimmune anti-Al serum, we have devised a microassay for the cytolytic capacity of mononuclear cell suspensions. The effector cells responsible for red -cell lysis are mononuclear, adherent and phagocytic, and their activity is blocked by aggregated IgG. Their presence correlates well with non-specific esterase-containing cells and we conclude that they are monocytes. Dose-response curves of red-cell lysis plotted against numbers of monocytes were used to derive a simple parameter expressing the number of monocytes needed to lyse 15o% of the 51Cr-labelled red cells.
The assay was applied to a group of 27 normal controls and 36 patients with a histologically proven diagnosis of malignant melanoma. The results indicate that monocytes from patients show significantly greater lytic activity than those from the controls. These data suggest that monocytes from cancer patients are in some way activated, and that other defects in monocyte function which have been detected in cancer patients (defective chemotaxis and maturation) may be associated with monocyte "activation".
THERE is increasing evidence for disordered monocyte and macrophage function in cancer patients. Dizon and Southam (1963) , using a skin-window technique, concluded that patients with malignant tumours have defective macrophage mobilization. Several studies have subsequently shown that the monocytes of cancer patients have defective chemotaxis (Boetcher and Leonard, 1974; Hausman et al., 1975; McVie, Logan and Kay, 1977) . Our own studies indicate that the maturation of monocytes into macrophages is also inhibited in cancer patients (Currie and Hedley, 1977) . Counter to this general theme of depressed monocyte-macrophage function, Lobuglio (1970) and recently Rhodes (1977) have shown that the monocytes of cancer patients have increased expression of surface Fc receptors.
Since Holm and Hammarstrom (1973) have shown that human peripheral blood monocytes will lyse antibody-coated human erythrocytes, we have adapted this phenomenon to develop an assay for the detection of disordered monocyte function in patients with malignant melanoma.
MATERIALS AND METHODS
Patients studied.-Blood samples were obtained from 36 patients with a histologically proven diagnosis of malignant melanoma.
Following detailed clinical investigation, the untreated patients could be classified into 2 broad groups: 10 patients had clinically detectable residual, recurrent or disseminated disease, and 11 patients who, while clinically "disease-free", had a very high risk of recurrence, and could therefore be considered to have minimal residual disease. The blood samples for assay were taken at least 2 weeks after any surgery and before cytotoxic chemotherapy, irradiation or immunological treatment. There w,ere also 19 patients studied after eytotoxic chemotherapy and/or immunotherapy. Four of these patients were studied both before and after cytotoxic chemotherapy. Samples were also obtained from 27 normal healthy volunteers.
Preparation of mononuclear cell suspensions. Preliminary experiments indicated that preservative-free heparin inhibited monocyte-mediated lysis, and in consequence all these experiments used defibrinated blood. About 10 ml of defibrinated venous blood were diluted and layered on to FicollHypaque (Lymphoprep. Nyegaard) and centrifuged as described by Boyum (1968) . The mononuclear cell (MNC) band was carefully removed, washed x 3 in Medium 199 and counted in a haemocytometer.
Enzyme cytochemistry.-Samples of the MNC suspension were placed on to glass slides, air-dried and fixed in formol-acetone at 4°C for 30 sec. They were then stained for non-specific esterase (NSE) and chloroacetate esterase (CAE) by the methods of Yam, Li and Crosby (1971 The requirement for intimate cell contact between effector and target cells was tested by examining the extent of targetcell lysis in microplates not subjected to centrifugation before incubation. As can be seen in Fig. 3 , the prior gentle centrifugation is essential to provide significant lysis after 2 h incubation, suggesting that close apposition between monocyte and red cell is necessary for lysis. We therefore conclude, as did Holm and Hammarstrom (1973) , that red-cell lysis is a consequence of close cell-surface contact and subsequent phagocytosis. used since in that form the data appear to be normally distributed and are therefore suitable for parametric statistical evaluation. Histograms were constructed for the EL15 for all normal donors and melanoma patients (Fig. 6 ).
Lytic activity of patients' monocytes
The data obtained from the normal donors and patients are shown as the EL15 in the Table. When the data from all the patients were compared to the normal donors it is clear that there is a significant difference (P < 0 01 in the two-sample t test) with the patients having the lower EL15. However, using the same test for signifi- Fig. 5 , it can be shown that, in the normal donor illustrated, 038 erythrocytes were lysed by each monocyte, whereas the patient gave a value of 1. 0 red cells/monocyte (i.e. at 15% release the patient's monocytes showed -,3 x the normal lytic activity).
Four of the patients were tested before and after chemotherapy and there was no evidence of any significant effect on monocyte-mediated lysis. However, the chemotherapy was given in high doses at monthly intervals, and the observations in these 4, and indeed in all 19 treated patients, were made 2 to 4 weeks after the last dose of drug.
DISCUSSION
We have adapted the phenomenon of monocyte-mediated lysis of antibodycoated human red cells, described originally by Holm and Hammarstr6m (1973) King, Bain and Lobuglio (1975) have claimed that the monocytes of patients with either tuberculosis or cancer show increased staphylocidal activity, and suggest that this is a consequence of monocyte activation, since HMPS activity is also increased in some cancer patients (King, Lobuglio and Sagone, 1977) as is the expression of Fc receptors (Lobuglio, 1970; Rhodes, 1977) . Poplack et al. (1976) have also used the lysis of antibody-coated human erythrocytes as an assay for monocyte function, and have applied it to patients with Wiskott-Aldrich syndrome. Despite normal peripheral-blood monocyte counts these patients showed a severe defect in monocyte lytic activity. The peripheral-blood monocyte counts in our patients were also within the normal range, and our data indicate an increase in monocyte lytic activity in malignant melanoma.
Currently available information suggests that the monocytes of cancer patients show depressed chemotaxis and depressed maturation, but these defects are associated with enhanced Fc receptor expression, increased staphylocidal activity, increased hexose-monophosphate shunt activity and, from our present work, an increase in the capacity to lyse antibodycoated erythrocytes. These features could all be the consequence of monocyte "activation". A cell whose metabolic and enzymatic activities have been stimulated may well lose the capacity to respond to chemotactic stimuli and to mature. Such an hypothesis may also explain the data of Eccles and Alexander (1974) who showed that in animals bearing tumours with a high macrophage content there is a substantial defect in their capacity to mount a monocyte/macrophage infiltrate at distant sites of inflammation. Since, as they have shown, this is not due to a quantitative monocyte deficiency, an intrinsic qualitative change in monocyte function may be responsible. "Activation", possibly mediated by immune complexes, could well account for these observations. However, the nature of the stimulus responsible for monocyte activation in our patients is as yet unclear. Pike and Snyderman (1976) have suggested that decreased macrophage chemotaxis in tumour-bearing animals may be mediated by a humoral factor. An investigation of the role of serum components in several assays of monocyte function will be published separately. 
